Story perspectives

Eli Lilly's Drug Advances as Obesity Market Soars

1/6/2026

Summary

Story summary

In 2025, Eli Lilly and Company achieved clinical-trial progress with its oral GLP-1 drug, while TIGIT therapy faced setbacks.
Key 2026 trials include Novartis' pelacarsen, Vertex's povetacicept, and Eli Lilly and Company's remternetug.
Eli Lilly and Company's retatrutide shows promising obesity-weight loss results.
Analysts project the Lp(a)-targeted therapy market could exceed $8.5 billion by 2033.
The first half of 2026 is poised for impactful clinical readouts across multiple therapeutic areas.

1 of 1

Story summary

In 2025, Eli Lilly and Company achieved clinical-trial progress with its oral GLP-1 drug, while TIGIT therapy faced setbacks.
Key 2026 trials include Novartis' pelacarsen, Vertex's povetacicept, and Eli Lilly and Company's remternetug.
Eli Lilly and Company's retatrutide shows promising obesity-weight loss results.
Analysts project the Lp(a)-targeted therapy market could exceed $8.5 billion by 2033.
The first half of 2026 is poised for impactful clinical readouts across multiple therapeutic areas.